Product Description
Mechanisms of Action: Magainin-2 Analogue
Novel Mechanism: Yes
Modality: Peptide/Protein
Route of Administration: Topical
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Abeona
Company Location: NEW YORK NY 10019
Company CEO: Vishwas Seshadri
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Diabetic Foot|Communicable Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| OneStep-1 | P3 |
Completed |
Diabetic Foot|Communicable Diseases |
2016-08-01 |
|
| OneStep-2 | P3 |
Completed |
Communicable Diseases|Diabetic Foot |
2016-07-01 |
|
| MSI-78-303 | P3 |
Completed |
Diabetic Foot |
1996-07-01 |
73% |
| MSI-78-304 | P3 |
Completed |
Diabetic Foot |
1996-07-01 |
73% |